IDEC Pharmaceuticals Corp
Article Abstract:
90% of IDEC Pharmaceuticals' 2002 revenues were derived from its product Rituxan and this is also expected in 2003 but may taper off in 2004. Equity has long-term capital-gains potential and unless a new product is developed, earnings growth rate may diminish out to 2006-20 08.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Forecasts, trends, outlooks, Marketing procedures, Financial management, Labor Distribution by Employer, Pharmaceutical industry, Finance, Marketing, Company investment, Investments, Statistics, Company marketing practices, Company business forecast/projection, Company forecasts, Rituxan (Medication), IDEC Pharmaceuticals
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Chiron
Article Abstract:
A comparative analysis of the company sales and earnings and the financial details of Chiron from 1988 - 2003 are illustrated. Projections of the equity price of this company for 2004 - 2005 is made using Value Line estimates.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
Drugs, Biological products industry, Chiron Corp., CHIR
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Securities, Company sales and earnings, Company earnings/profit, Company securities
Similar abstracts:
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.